Browse

Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD

Cited 16 time in Web of Science Cited 17 time in Scopus
Authors
Kim, Yeni; Shin, Min-Sup; Kim, Jae-Won; Yoo, Hee-Jung; Cho, Soo-Churl; Kim, Boong-Nyun
Issue Date
2009-02-20
Publisher
Wiley-Blackwell
Citation
Hum Psychopharmacol Clin Exp 2009 ;24(2):95-102.
Keywords
Administration, OralAttention Deficit Disorder with Hyperactivity/*drugtherapy/physiopathologyCentral Nervous System Stimulants/*administration & dosageChildCognition Disorders/*drug therapy/etiologyDelayed-Action PreparationsFemaleHumansLinear ModelsMaleMethylphenidate/*administration & dosageNeuropsychological TestsReaction Time/drug effects
Abstract
OBJECTIVES: This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH). METHODS: 102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH. RESULTS: There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT. CONCLUSIONS: These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings.
ISSN
1099-1077 (Electronic)
0885-6222 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19226534

https://hdl.handle.net/10371/63327
DOI
https://doi.org/10.1002/hup.1010
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Psychiatry (정신과학전공)Journal Papers (저널논문_정신과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse